Carolyn Bland
Medical · Wichita, KSNPI 1679616478
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 256 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 40 manufacturers, the largest accounting for just 15.2% — the pattern of someone who eats at a lot of different presentations.
Across 256 payments — averaging $16.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$630
- AstraZeneca$461
- Lilly USA, LLC$450
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$429
- Pfizer$212
- Novo Nordisk$176
- plus $2K from 34 others
What the payments were for
- Food & beverage$4,136100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 47 | $630 |
| AstraZeneca | 26 | $461 |
| Lilly USA, LLC | 36 | $450 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 26 | $429 |
| Pfizer | 12 | $212 |
| Novo Nordisk | 6 | $176 |
| GSK | 10 | $173 |
| Merck | 10 | $153 |
| Abbott | 7 | $144 |
| Amarin Pharma, Inc. | 9 | $139 |
| Bayer | 8 | $130 |
| Johnson & Johnson | 9 | $129 |
| Amgen | 7 | $111 |
| Sumitomo Pharma America, Inc. | 6 | $102 |
| Boehringer Ingelheim | 3 | $57 |
| Sanofi Pasteur Inc. | 3 | $56 |
| Cranial Technologies, Inc | 2 | $44 |
| Xeris Pharmaceuticals, Inc. | 2 | $43 |
| IBSA Pharma Inc. | 2 | $43 |
| Astellas Pharma US Inc | 2 | $42 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $36 |
| Eisai Inc. | 2 | $34 |
| Mylan Specialty L.p. | 2 | $27 |
| CSL Behring | 1 | $26 |
| Vanda Pharmaceuticals Inc. | 1 | $26 |
| Ardelyx, Inc. | 1 | $25 |
| Antares Pharma, Inc. | 1 | $23 |
| Seqirus USA Inc | 1 | $22 |
| Daiichi Sankyo Inc. | 1 | $21 |
| Exact Sciences | 1 | $19 |
| Medtronic | 1 | $18 |
| Sunovion Pharmaceuticals Inc. | 1 | $18 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $17 |
| Sanofi-aventis U.S. LLC | 1 | $17 |
| Dexcom, Inc. | 1 | $17 |
| Kowa Pharmaceuticals America, Inc. | 1 | $15 |
| Lundbeck LLC | 1 | $14 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $14 |
| Genentech USA, Inc. | 1 | $13 |
| Collegium Pharmaceutical, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RYBELSUS$106
How this compares
$4,136 in reported general payments places this provider in the 80th percentile of 205 medical providers in Kansas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 36 | $40,353 |
| JanuviaSitagliptin Phosphate | 17 | $26,333 |
| EliquisApixaban | 24 | $19,200 |
| LinzessLinaclotide | 28 | $18,269 |
| TradjentaLinagliptin | 22 | $15,447 |
| MyrbetriqMirabegron | 22 | $13,587 |
| GraliseGabapentin | 12 | $13,038 |
| XareltoRivaroxaban | 13 | $11,766 |
| OxycontinOxycodone Hcl | 13 | $9,903 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 14 | $6,765 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 154 | $6,419 |
| VascepaIcosapent Ethyl | 11 | $5,331 |
| Duloxetine Hcl | 50 | $4,024 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 83 | $4,011 |
| Baclofen | 78 | $2,097 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $176 | $40,35336 claims |
| MerckJanuvia | $153 | $26,33317 claims |
| Boehringer IngelheimTradjenta, Combivent Respimat | $57 | $22,21236 claims |
| PfizerEliquis | $212 | $19,20024 claims |
| AbbVieLinzess | $630 | $18,26928 claims |
| Astellas Pharma US IncMyrbetriq | $42 | $13,58722 claims |
| Johnson & JohnsonXarelto | $129 | $11,76613 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 205 medical providers in Kansas.
Other medical in Wichita
- Richard AllenbachWichita$70K
- Kathryn WelchWichita$32K
- Jason MengesWichita$15K
- Trang BrownleeWichita$11K
- Susan GeorgeWichita$10K
- Andrew OsbeckWichita$9K
- Lisa HarrisWichita$8K
- Christiane YourdonWichita$6K
- Kristen OchsnerWichita$5K
- Kristen WolfWichita$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.